Pharmagreen Biotech Inc. (PHBI) Stock Price & Analysis
Pharmagreen Biotech Inc. (PHBI) fell 16.67% to USD 0 as of July 25, 2026 at 19:03 UTC, according to Nexqual real-time market data.
PHBI last closed at USD 0; the session ranged USD 0–0 on volume of 630 shares. Market capitalization is $518,509, with a 52-week range of USD 0–0 (OID). Source: Nexqual, July 25, 2026 at 19:03 UTC.
Key Statistics (as of July 25, 2026 at 19:03 UTC)
| Price | USD 0 |
|---|---|
| Change | ▼ 16.67% (down) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 630 shares |
| Market Cap | $518,509 |
| Exchange | OID |
Technical Analysis (PHBI)
Nexqual's technical model rates PHBI "SELL" based on 1 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 19:03 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 22.85 (oversold) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (PHBI)
Wall Street analysts rate PHBI "None", per Nexqual as of July 25, 2026 at 19:03 UTC.
| Consensus Rating | None |
|---|
Earnings (PHBI)
Source: Nexqual, July 25, 2026 at 19:03 UTC.
Financials & Fundamentals (PHBI)
| Total Revenue | $3,002 |
|---|---|
| Revenue Growth (YoY) | -33.00% |
| Gross Margin | +44.90% |
| Operating Margin | -7420.17% |
| Profit Margin | +0.00% |
| Current Ratio | 0.04 |
| Total Cash | $906 |
| Total Debt | $352,411 |
| Free Cash Flow | $-161,086 |
Source: Nexqual, July 25, 2026 at 19:03 UTC.
Financial Health Score (PHBI)
Nexqual rates Pharmagreen Biotech Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 19:03 UTC.
| Growth | Critical — Revenue -33% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $906 cash, no debt |
| Cash Flow | Weak — FCF negative: -$161K, burning cash |
| Efficiency | Mixed — No data |
Ownership (PHBI)
| Insider Ownership | +12.77% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 691.35M |
| Float | 625.17M |
Source: Nexqual, July 25, 2026 at 19:03 UTC.
Leadership (PHBI)
Pharmagreen Biotech Inc. is led by Peter Wojcik B.A. (age 53), President, CEO, Secretary, Treasurer & Director, per Nexqual as of July 25, 2026 at 19:03 UTC.
| President, CEO, Secretary, Treasurer & Director | Peter Wojcik B.A. (age 53) |
|---|---|
| CFO & Principal Accounting Officer | Terry Kwan B.Com., C.A. (age 77) |
From Pharmagreen Biotech Inc.'s Latest SEC 10-K Filing (filed 2023-01-17)
Partnerships
- The Company currently lacks funds with which to consummate the contemplated transaction and has not negotiated a definitive agreement with respect to the contemplated transaction.
- As a result of the merger, the Company changed its name to Air Transport Group Holdings, Inc.   On April 12, 2018, the Company entered into a share exchange agreement with WFS Pharmagreen Inc., a private company incorporated under the laws of British Columbia, Canada, whereby the Company acquired all of the issued and outstanding shares of WFS Pharmagreen Inc. in exchange for 37,704,500 shares of common stock of the Company.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| WDLF | Decentral Life, Inc. | USD 0 | ▼ 33.33% |
| HBRM | Herborium Group, Inc. | USD 0 | ▲ 0% |
| BEGI | BlackStar Enterprise Group, Inc | USD 0 | ▲ 0% |
| VDRM | ViaDerma, Inc. | USD 0 | ▲ 0% |
| GTLL | Global Technologies, Ltd. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 19:03 UTC. This page is informational and not investment advice.